AR002967A1 - Esteres y amidas de la 1,4-piperidina disustituida, sus sales de acidos aceptables desde el punto de vista fisiologico, un procedimiento para supreparacion y las preparaciones farmaceuticas que los/las contienen. - Google Patents
Esteres y amidas de la 1,4-piperidina disustituida, sus sales de acidos aceptables desde el punto de vista fisiologico, un procedimiento para supreparacion y las preparaciones farmaceuticas que los/las contienen.Info
- Publication number
- AR002967A1 AR002967A1 ARP960101670A AR10167096A AR002967A1 AR 002967 A1 AR002967 A1 AR 002967A1 AR P960101670 A ARP960101670 A AR P960101670A AR 10167096 A AR10167096 A AR 10167096A AR 002967 A1 AR002967 A1 AR 002967A1
- Authority
- AR
- Argentina
- Prior art keywords
- piperidine
- amides
- pharmaceutical preparations
- alkyl
- esters
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 3
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 title abstract 2
- 150000007513 acids Chemical class 0.000 title abstract 2
- 150000001408 amides Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- -1 hydroxy, benzyloxy, methylthiomethyl Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 230000008991 intestinal motility Effects 0.000 abstract 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000004899 motility Effects 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000033764 rhythmic process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003523 serotonin 4 antagonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Se describen nuevos ésteres y amidas farmacológicamente activos de la 1,4-piperidina disustituida como antagonista 5-HT4 de fórmula general (I), enla cual: A es de fórmula (a) en la cual R1 es alcoxi y R2 es halo o heterociclo de fórmulas b, cy d; donde R3 es H o halo; R4 es H o alquilo;R5 es H o alcoxi;R6 es H o alquilo; X representa oxígeno o NH; Y representa un grupo de fórmula -OR7 o NHR7, en las cuales R7 es alquilo C1-3, arilo o aralquilo; R representahidrógeno, fenilo, hidroxi, benciloxi, metiltiometilo, 3-indolilo, metoxi carbonilo o carbamoilo; y sus sales de adición de ácido con ácidosfarmacológicamente aceptables. También se describen los procedimientos para preparar estos compuestos, las preparaciones farmacéuticas que los contienen yel empleo de estas preparaciones para el tratamiento de pacientes que sufren trastornos del ritmo cardíaco, motilidad intestinal, ansiedad, depresión,psicosis, trastornos cognitivos trastornos de la motilidad, abuso del alcohol y migrana.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT95MI000491A IT1275903B1 (it) | 1995-03-14 | 1995-03-14 | Esteri e ammidi della 1,4-piperidina disostituita |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR002967A1 true AR002967A1 (es) | 1998-05-27 |
Family
ID=11370883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960101670A AR002967A1 (es) | 1995-03-14 | 1996-03-08 | Esteres y amidas de la 1,4-piperidina disustituida, sus sales de acidos aceptables desde el punto de vista fisiologico, un procedimiento para supreparacion y las preparaciones farmaceuticas que los/las contienen. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6002009A (es) |
| EP (1) | EP0815080B1 (es) |
| JP (1) | JP4021477B2 (es) |
| KR (1) | KR19980702972A (es) |
| AR (1) | AR002967A1 (es) |
| AT (1) | ATE269304T1 (es) |
| AU (1) | AU5101096A (es) |
| BG (1) | BG101711A (es) |
| BR (1) | BR9607347A (es) |
| CA (1) | CA2209904C (es) |
| CO (1) | CO4700521A1 (es) |
| CZ (1) | CZ285997A3 (es) |
| DE (1) | DE69632724T2 (es) |
| EE (1) | EE9700202A (es) |
| ES (1) | ES2224159T3 (es) |
| HR (1) | HRP960116A2 (es) |
| IL (1) | IL117446A0 (es) |
| IT (1) | IT1275903B1 (es) |
| NO (1) | NO974236L (es) |
| NZ (1) | NZ303941A (es) |
| PE (1) | PE7698A1 (es) |
| PL (1) | PL322211A1 (es) |
| SK (1) | SK121397A3 (es) |
| TR (1) | TR199700948T1 (es) |
| WO (1) | WO1996028424A1 (es) |
| YU (1) | YU14196A (es) |
| ZA (1) | ZA962009B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT832065E (pt) * | 1995-06-06 | 2002-02-28 | Pfizer | N-(indole-2-carbonil)-glicinamidas e seus derivados como agentes antidiabeticos |
| AU7001796A (en) * | 1995-09-22 | 1997-04-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and medicinal use thereof |
| TW445263B (en) | 1996-02-29 | 2001-07-11 | Janssen Pharmaceutica Nv | Novel esters of 1,4-disubstituted piperidine derivatives |
| US6339087B1 (en) | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| TW570920B (en) | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| GB0211230D0 (en) * | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
| GEP20084527B (en) * | 2003-09-03 | 2008-11-10 | Pfizer | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
| TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| US7728006B2 (en) * | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7737163B2 (en) * | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| AP2418A (en) * | 2004-06-15 | 2012-06-04 | Pfizer | Benzimidazolone carboxylic acid derivatives. |
| KR100875558B1 (ko) * | 2004-06-15 | 2008-12-23 | 화이자 인코포레이티드 | 벤즈이미다졸론 카복실산 유도체 |
| JP2008509088A (ja) * | 2004-09-02 | 2008-03-27 | ファイザー株式会社 | ベンズイミダゾロンカルボン酸誘導体 |
| ATE431824T1 (de) * | 2004-11-05 | 2009-06-15 | Theravance Inc | Chinolinon-carboxamid-verbindungen |
| ATE441646T1 (de) * | 2004-11-05 | 2009-09-15 | Theravance Inc | 5-ht4-rezeptoragonistenverbindungen |
| MX2007007818A (es) * | 2004-12-22 | 2007-09-11 | Theravance Inc | Compuestos de indazol-carboxamida. |
| ES2366375T3 (es) * | 2005-02-22 | 2011-10-19 | Pfizer, Inc. | Derivados de oxiindol, como agonistas del receptor 5-ht4. |
| NZ560828A (en) * | 2005-03-02 | 2011-01-28 | Theravance Inc | Quinolinone compounds as 5-HT4 receptor agonists |
| WO2006133104A2 (en) * | 2005-06-07 | 2006-12-14 | Theravance, Inc. | Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists |
| MY143574A (en) * | 2005-11-22 | 2011-05-31 | Theravance Inc | Carbamate compounds as 5-ht4 receptor agonists |
| US8642772B2 (en) * | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| US8232315B2 (en) * | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| US8927602B2 (en) | 2009-11-06 | 2015-01-06 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| KR101783632B1 (ko) | 2009-11-06 | 2017-10-10 | 에스케이바이오팜 주식회사 | 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법 |
| ES2691671T3 (es) | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103862D0 (en) * | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
| GB9204565D0 (en) * | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
| WO1994008965A1 (en) * | 1992-10-16 | 1994-04-28 | Smithkline Beecham Plc | N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists |
| EP0774460A1 (en) * | 1994-03-30 | 1997-05-21 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compound and use thereof as medicine |
-
1995
- 1995-03-14 IT IT95MI000491A patent/IT1275903B1/it active IP Right Grant
-
1996
- 1996-03-04 NZ NZ303941A patent/NZ303941A/en unknown
- 1996-03-04 PL PL96322211A patent/PL322211A1/xx unknown
- 1996-03-04 CZ CZ972859A patent/CZ285997A3/cs unknown
- 1996-03-04 US US08/913,425 patent/US6002009A/en not_active Expired - Lifetime
- 1996-03-04 EP EP96907342A patent/EP0815080B1/en not_active Expired - Lifetime
- 1996-03-04 CA CA002209904A patent/CA2209904C/en not_active Expired - Lifetime
- 1996-03-04 AU AU51010/96A patent/AU5101096A/en not_active Abandoned
- 1996-03-04 KR KR1019970706380A patent/KR19980702972A/ko not_active Withdrawn
- 1996-03-04 TR TR97/00948T patent/TR199700948T1/xx unknown
- 1996-03-04 DE DE69632724T patent/DE69632724T2/de not_active Expired - Lifetime
- 1996-03-04 AT AT96907342T patent/ATE269304T1/de active
- 1996-03-04 ES ES96907342T patent/ES2224159T3/es not_active Expired - Lifetime
- 1996-03-04 WO PCT/EP1996/000903 patent/WO1996028424A1/en not_active Ceased
- 1996-03-04 SK SK1213-97A patent/SK121397A3/sk unknown
- 1996-03-04 EE EE9700202A patent/EE9700202A/xx unknown
- 1996-03-04 JP JP52723396A patent/JP4021477B2/ja not_active Expired - Lifetime
- 1996-03-04 BR BR9607347A patent/BR9607347A/pt not_active Application Discontinuation
- 1996-03-05 PE PE1996000151A patent/PE7698A1/es not_active Application Discontinuation
- 1996-03-08 AR ARP960101670A patent/AR002967A1/es unknown
- 1996-03-11 YU YU14196A patent/YU14196A/sh unknown
- 1996-03-12 IL IL11744696A patent/IL117446A0/xx unknown
- 1996-03-13 CO CO96012408A patent/CO4700521A1/es unknown
- 1996-03-13 ZA ZA9602009A patent/ZA962009B/xx unknown
- 1996-03-13 HR HRMI95A000491A patent/HRP960116A2/hr not_active Application Discontinuation
-
1997
- 1997-07-01 BG BG101711A patent/BG101711A/xx unknown
- 1997-09-12 NO NO974236A patent/NO974236L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2209904C (en) | 2007-11-13 |
| NZ303941A (en) | 1998-11-25 |
| NO974236D0 (no) | 1997-09-12 |
| EE9700202A (et) | 1998-02-16 |
| ZA962009B (en) | 1997-09-15 |
| JP4021477B2 (ja) | 2007-12-12 |
| DE69632724D1 (de) | 2004-07-22 |
| US6002009A (en) | 1999-12-14 |
| IL117446A0 (en) | 1996-07-23 |
| NO974236L (no) | 1997-09-12 |
| YU14196A (sh) | 1999-03-04 |
| ITMI950491A1 (it) | 1996-09-14 |
| CA2209904A1 (en) | 1996-09-19 |
| PL322211A1 (en) | 1998-01-19 |
| ITMI950491A0 (it) | 1995-03-14 |
| HRP960116A2 (en) | 1997-10-31 |
| DE69632724T2 (de) | 2005-07-07 |
| SK121397A3 (en) | 1998-02-04 |
| BR9607347A (pt) | 1997-12-30 |
| WO1996028424A1 (en) | 1996-09-19 |
| TR199700948T1 (xx) | 1998-03-21 |
| MX9706826A (es) | 1997-11-29 |
| JPH11501640A (ja) | 1999-02-09 |
| ES2224159T3 (es) | 2005-03-01 |
| EP0815080A1 (en) | 1998-01-07 |
| AU5101096A (en) | 1996-10-02 |
| CO4700521A1 (es) | 1998-12-29 |
| PE7698A1 (es) | 1998-03-11 |
| KR19980702972A (ko) | 1998-09-05 |
| ATE269304T1 (de) | 2004-07-15 |
| CZ285997A3 (cs) | 1998-02-18 |
| BG101711A (en) | 1998-02-27 |
| EP0815080B1 (en) | 2004-06-16 |
| IT1275903B1 (it) | 1997-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR002967A1 (es) | Esteres y amidas de la 1,4-piperidina disustituida, sus sales de acidos aceptables desde el punto de vista fisiologico, un procedimiento para supreparacion y las preparaciones farmaceuticas que los/las contienen. | |
| AR009985A1 (es) | Aminotiofencarboxamidas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas | |
| AR024819A1 (es) | Derivados de la n-(indolcarbonil)-piperazina, un procedimiento para su preparacion, su empleo para preparar un medicamento, los medicamentos a base de los mismos y las preparaciones farmaceuticas que los contienen. | |
| BR9813360A (pt) | Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz (mmp) | |
| DE3876877D1 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
| MY102866A (en) | Amide derivatives. | |
| DK0490772T3 (da) | 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem | |
| FI943948A0 (fi) | Heterosykliset hiilihappojohdannaiset | |
| NO944564D0 (no) | Indolcarbazol-imider og deres anvendelse | |
| FI80877B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara spiro/4,(3+n)/-2-azaalkan-3-karboxylsyraderivat och vid framstaellning av dessa anvaendbara foerening. | |
| ATE185345T1 (de) | 1,4-disubstituierte piperazine zur behandlung von erkrankungen des zentralnervensystems und von nervenendokrinen erkrankungen | |
| AR002732A1 (es) | Derivados de 1,3-dihidro-1-(fenilalquilo)-2-h-imidazol-2-ona, uso de los derivados para preparar un medicamento, composiciones farmacéuticas que contienen dichos derivados, un procedimiento para su preparación, y un procedimiento para preparar dichos derivados | |
| UY23624A1 (es) | Procedimiento para la preparacion de nuevos derivados de indol | |
| PE20040911A1 (es) | Derivados de 3h-quinazolin-4-ona como inhibidores selectivos de la monoaminooxidasa b | |
| DE3873578D1 (de) | Verwendung von tetrahydrobenz(c,d)indol-6-carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden. | |
| DE68908145D1 (de) | Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien. | |
| US4764514A (en) | Oxothiazolidine compound and composition containing same | |
| ATE67756T1 (de) | N-substituierte 3-piperidin- oder 3pyridincarbons|uren und deren derivate. | |
| ATE507226T1 (de) | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung | |
| AR024818A1 (es) | Derivados de la n-(indolcarbonil)-piperazina, un procedimiento para su preparacion, su empleo para preparar un medicamento, los medicamentos a base de losmismos y las preparaciones farmaceuticas que los contienen. | |
| FI853233L (fi) | 1,6-naftyridinderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska produkter. | |
| AR033779A1 (es) | Compuestos utiles en la enfermedad de reflujo | |
| ATE52776T1 (de) | 1-phenyl-3-benzazepine. | |
| EP0207483A3 (en) | Benzimidazoles, process for their preparation, medicaments containing them and intermediates | |
| ATE181503T1 (de) | Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution |